NCT03131973View on ClinicalTrials.gov

Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 13, 2017

Primary Completion Date

November 5, 2017

Study Completion Date

November 10, 2017

Conditions
Rheumatoid Arthritis
Interventions
DRUG

BMS-986195

Specified dose on specified days

DRUG

Methotrexate

Specified dose on specified days

DRUG

Leucovorin

Specified dose on specified days

DRUG

Caffeine

Specified dose on specified days

DRUG

Montelukast

Specified dose on specified days

DRUG

Flurbiprofen

Specified dose on specified days

DRUG

Omeprazole

Specified dose on specified days

DRUG

Midazolam

Specified dose on specified days

DRUG

Digoxin

Specified dose on specified days

DRUG

Pravastatin

Specified dose on specified days

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY